PubMed-compiled information sheet
This sheet was compiled from PubMed (NIH) abstracts using AI assistance. Every factual claim is cited to a real PubMed article (see the source list). It has not yet been human-reviewed — confirm with a healthcare provider before use.
Compiled from 26 PubMed articles · model: gemma4:31b
Summary
Background
Traditional uses
Active compounds
Mechanism of action
Clinical evidence
Aqueous extracts of cerasee fruit reduced hyperglycemia by 50% after 5 hours in streptozotocin-induced diabetic mice and improved glucose tolerance in normal mice [PMID:3899464].
Wild Bitter Melon (400 mg/kg daily) was investigated for its therapeutic potential to ameliorate immobility-induced muscle atrophy in a murine model [PMID:39086863].
Total phenolic extract of WBM leaf attenuated P. acnes-induced ear swelling and microabscesses in mice and suppressed pro-inflammatory cytokines (IL-8, IL-1β, TNF-α) in vitro [PMID:26098998, PMID:26624580].
Charantadiol A from WBM leaf significantly suppressed P. gingivalis-stimulated IL-6 and TNF-α in a periodontitis mouse model [PMID:34577123].
Ethanol extract of wild bitter melon demonstrated antibacterial and anti-biofilm activities against Streptococcus mutans and Lactobacillus acidophilus in vitro [PMID:41690644].
Evidence summary
PubMed sources
- 1.PMID: 36634725 (2023) — Effects of dietary wild bitter melon (Momordica charantia var. abbreviate Ser.) extract on glucose and lipid metabolism in HFD/STZ-induced type 2 diabetic rats. · Journal of ethnopharmacology
- 2.PMID: 31151277 (2019) — Investigation of Biological Activities of Wild Bitter Melon (Momordica charantia Linn. Var. Abbreviata Ser.). · Biomolecules
- 3.PMID: 39086863 (2024) — The therapeutic potential of Wild Bitter Melon to ameliorate muscle atrophy in a murine model. · Avicenna journal of phytomedicine
- 4.PMID: 41690644 (2026) — Anticariogenic potential, phytochemical and molecular docking analysis of Momordica charantia: An in vitro study. · Microbial pathogenesis
- 5.PMID: 26624580 (2015)